Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 125.26 Billion KRW | 0.8% |
| 2022 | 124.26 Billion KRW | 114.97% |
| 2021 | 57.8 Billion KRW | 362.56% |
| 2020 | 12.49 Billion KRW | -32.5% |
| 2019 | 18.51 Billion KRW | -18.27% |
| 2018 | 22.65 Billion KRW | 129.81% |
| 2017 | 9.85 Billion KRW | 4.73% |
| 2016 | 9.41 Billion KRW | 71.75% |
| 2015 | 5.48 Billion KRW | 164.18% |
| 2014 | -8.53 Billion KRW | -125.66% |
| 2013 | -3.78 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 159.22 Billion KRW | 2.49% |
| 2024 Q1 | 155.35 Billion KRW | 24.03% |
| 2023 Q4 | 125.26 Billion KRW | -21.93% |
| 2023 FY | 125.26 Billion KRW | 0.8% |
| 2023 Q1 | 134.81 Billion KRW | 8.48% |
| 2023 Q2 | 143.12 Billion KRW | 6.17% |
| 2023 Q3 | 160.45 Billion KRW | 12.1% |
| 2022 Q2 | 96.51 Billion KRW | 16.83% |
| 2022 Q3 | 117.01 Billion KRW | 21.25% |
| 2022 FY | 124.26 Billion KRW | 114.97% |
| 2022 Q1 | 82.61 Billion KRW | 42.91% |
| 2022 Q4 | 124.26 Billion KRW | 6.2% |
| 2021 Q2 | 75.45 Billion KRW | 241.09% |
| 2021 Q4 | 57.8 Billion KRW | -30.07% |
| 2021 Q3 | 82.66 Billion KRW | 9.56% |
| 2021 FY | 57.8 Billion KRW | 362.56% |
| 2021 Q1 | 22.12 Billion KRW | 84.59% |
| 2020 Q2 | 15.66 Billion KRW | -21.71% |
| 2020 Q3 | 17.85 Billion KRW | 13.98% |
| 2020 FY | 12.49 Billion KRW | -32.5% |
| 2020 Q1 | 20 Billion KRW | 15.58% |
| 2020 Q4 | 11.98 Billion KRW | -32.87% |
| 2019 Q3 | 25.26 Billion KRW | 9.81% |
| 2019 Q2 | 23.01 Billion KRW | 1.87% |
| 2019 Q1 | 22.58 Billion KRW | -0.29% |
| 2019 FY | 18.51 Billion KRW | -18.27% |
| 2019 Q4 | 17.3 Billion KRW | -31.51% |
| 2018 Q4 | 22.65 Billion KRW | 1.7% |
| 2018 Q2 | 21.18 Billion KRW | 103.08% |
| 2018 Q1 | 10.42 Billion KRW | 5.8% |
| 2018 FY | 22.65 Billion KRW | 129.81% |
| 2018 Q3 | 22.27 Billion KRW | 5.17% |
| 2017 Q3 | 10.05 Billion KRW | -32.41% |
| 2017 Q4 | 9.85 Billion KRW | -2.01% |
| 2017 FY | 9.85 Billion KRW | 4.73% |
| 2017 Q1 | 11.4 Billion KRW | 21.17% |
| 2017 Q2 | 14.88 Billion KRW | 30.51% |
| 2016 Q1 | 3.6 Billion KRW | -38.63% |
| 2016 FY | 9.41 Billion KRW | 71.75% |
| 2016 Q4 | 9.41 Billion KRW | 16.59% |
| 2016 Q3 | 8.07 Billion KRW | 93.33% |
| 2016 Q2 | 4.17 Billion KRW | 15.72% |
| 2015 Q3 | -555.34 Million KRW | 94.66% |
| 2015 Q2 | -10.4 Billion KRW | -18.94% |
| 2015 Q1 | -8.74 Billion KRW | -2.45% |
| 2015 FY | 5.48 Billion KRW | 164.18% |
| 2015 Q4 | 5.87 Billion KRW | 1158.8% |
| 2014 FY | -8.53 Billion KRW | -125.66% |
| 2014 Q4 | -8.53 Billion KRW | 28.75% |
| 2014 Q2 | -10.45 Billion KRW | 22.03% |
| 2014 Q1 | -13.41 Billion KRW | -254.45% |
| 2014 Q3 | -11.98 Billion KRW | -14.61% |
| 2013 FY | -3.78 Billion KRW | 0.0% |
| 2013 Q3 | -19.2 Billion KRW | 0.0% |
| 2013 Q4 | -3.78 Billion KRW | 80.29% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| HLB Co., Ltd. | -46.18 Billion KRW | 371.229% |
| iNtRON Biotechnology, Inc. | -40.58 Billion KRW | 408.644% |
| BINEX Co., Ltd. | 45.34 Billion KRW | -176.229% |
| Bioneer Corporation | -3.9 Billion KRW | 3305.461% |
| Anterogen.Co.,Ltd. | 8.35 Billion KRW | -1399.831% |
| MEDIPOST Co., Ltd. | 14.81 Billion KRW | -745.552% |
| CrystalGenomics, Inc. | 8.99 Billion USD | -1293.06% |
| Helixmith Co., Ltd | -24.42 Billion KRW | 612.83% |
| Chabiotech Co.,Ltd. | 388.94 Billion KRW | 67.794% |
| Medy-Tox Inc. | 49.58 Billion KRW | -152.626% |
| Peptron, Inc. | 4.86 Billion KRW | -2472.853% |
| Genexine, Inc. | 61.39 Billion KRW | -104.025% |
| HLB Therapeutics Co.,Ltd. | -13.68 Billion KRW | 1015.209% |
| LegoChem Biosciences, Inc. | -56.05 Billion KRW | 323.47% |
| ALTEOGEN Inc. | 53.56 Billion KRW | -133.83% |
| PharmaResearch Co., Ltd. | -32.93 Billion KRW | 480.294% |
| SillaJen, Inc. | -13.89 Billion KRW | 1001.716% |
| JETEMA, Co., Ltd. | 84.27 Billion KRW | -48.628% |
| OliX Pharmaceuticals,Inc | 27.37 Billion KRW | -357.584% |
| Genomictree Inc. | -43.43 Billion KRW | 388.39% |
| MedPacto, Inc. | -64 Billion KRW | 295.721% |
| D&D Pharmatech | -7.5 Billion KRW | 1768.432% |
| EASY BIO,Inc. | 53.21 Billion KRW | -135.409% |
| GI Innovation, Inc. | -4.82 Billion KRW | 2697.46% |